ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO982

Albuminuria-Lowering Effect of Sodium-Glucose Cotransporter 2 Inhibitors, Finerenone, and Their Combination in Patients with CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Hanouneh, Mohamad A., Johns Hopkins University, Baltimore, Maryland, United States
  • Cervantes, Carmen Elena, Johns Hopkins University, Baltimore, Maryland, United States
  • Lim, Jonathan G., Johns Hopkins University, Baltimore, Maryland, United States
  • Acharya, Veena K., Johns Hopkins University, Baltimore, Maryland, United States
  • Hanouneh, Tareq, Mayo Clinic in Florida, Jacksonville, Florida, United States
  • Lim, Hyung M., Johns Hopkins University, Baltimore, Maryland, United States

Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2is) and Finerenone reduce urine albumin-to-creatinine ratio (UACR) and confer kidney and cardiovascular protection in patients with Chronic Kidney Disease (CKD).


We conducted a retrospective study in patients seen in a community nephrology practice with eGFR 25-90 ml/min per 1.73 m2 and UACR ≥30 mg/g Cr. Patients were stratified into 3 groups: 8 months treatment period with SGLT2is, 4 months treatment period with Finerenone, and 8 months with combination therapy (SGLT2i for 4 months followed by SGLT2i and Finerenone for additional 4 months). The outcome was the percent change in UACR from baseline.


Of 402 patients screened between 1/2022 and 9/2023, 85 were included with mean eGFR, 51.5 ml/min per 1.73 m2, and median UACR 594 mg/g. 47 patients received SGLT2i (dapagliflozin 10 mg/day or empagliflozin 10 mg/day), 19 received Finerenone (20 mg/d for eGFR > 60 or 10 mg/d for eGFR 25-60, and 19 were on combination therapy.

The mean percentage change from baseline in UACR in the SGLT2is group and Finereone group was -46.35% (95% CI, -53.39 to -39.31) and -44.65% (95% CI, -68.67, -20.64), respectively. SGLT2i-Finerenone combination therapy decreased UACR by -65.5% (95% CI, -71.82, -59.17; P<0.001 vs SGLT2i; P=0.04 vs Finerenone) (Fig 1). Compared with the Finerenone group, the mean change in serum potassium level (mmol/L) was significantly lower in the combination group (+ 0.3 vs -0.02, P=0.01). (Fig 2)


Combining dapagliflozin or empagliflozin with Finerenone resulted in a significantly additive UACR-lowering effect with a significant decrease in the risk of hyperkalemia.